Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 8/20 | 0.34 |
| ▸ | CNR1 | P21554 | 4/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 7/20 | 0.33 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.33 |
| ▸ | RARA | P10276 | 1/20 | 0.30 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
| ▸ | RARG | P13631 | 1/20 | 0.30 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3340563 | 0.89 | S1PR1 (0.38) | S1PR1S1PR5RARARARBRARG | |
| SCHEMBL13330803 | 0.81 | CNR2 (0.33) | CNR2CNR1S1PR1 | |
| SCHEMBL3342731 | 0.81 | CNR2 (0.33) | CNR2CNR1S1PR1S1PR5 | |
| SCHEMBL13303833 | 0.77 | SMN1; SMN2 (0.39) | CNR2CNR1S1PR1RARARARB | |
| SCHEMBL3343532 | 0.76 | CNR2 (0.34) | CNR2CNR1S1PR1S1PR5S1PR3 | |
| SCHEMBL3342478 | 0.75 | S1PR1 (0.37) | KITCNR2CNR1S1PR1S1PR5 | |
| SCHEMBL3340738 | 0.75 | S1PR1 (0.37) | CNR2CNR1S1PR1S1PR5S1PR3 | |
| SCHEMBL13330767 | 0.74 | S1PR1 (0.34) | KITCNR2CNR1S1PR1S1PR5 | |
| SCHEMBL3340196 | 0.73 | S1PR1 (0.38) | CNR2CNR1S1PR1S1PR5RARA | |
| SCHEMBL3347312 | 0.70 | CNR2 (0.42) | CNR2CNR1S1PR1S1PR5RARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | EXELIXIS, INC. (US) | 2010-06-24 | — | — | US | disclosed |
| WO-2010065760-A1 | IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION | EXELIXIS, INC. (US) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160369-A1 | S1P1 Agonists and Methods of Making And Using | S1PR1, S1PR5, S1PR3 | KIT 461/4885CNR2 35/4885CNR1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.